The Medical Letter on Drugs and Therapeutics
Choice of Drug-Eluting Stents
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The use of intracoronary stents in angioplasty procedures has improved both short- and long-term success rates. In recent years, drug-eluting stents (DESs) have largely replaced bare-metal stents (BMSs).1

BARE-METAL STENTS — Intracoronary stents are safer and more effective than balloon angioplasty for most percutaneous coronary interventions. They have markedly reduced the incidence of periprocedural complications, but are associated with high rates (20-25%) of restenosis. Restenosis is a biological response of the vessel to mechanical injury. Local barotrauma to the vessel from balloons or stents results in neointimal proliferation within the stents that narrows the lumen. Restenosis usually occurs during the first 6-9 months after a balloon angioplasty or insertion of a BMS. The risk of in-stent restenosis is increased in patients with diabetes, small-diameter vessels, long ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Choice of Drug-Eluting Stents
Article code: 1406b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian